Skip to main content
Book cover

Leukemia Stem Cells pp 77–94Cite as

PCR Technology to Identify Minimal Residual Disease

Part of the Methods in Molecular Biology book series (MIMB,volume 2185)

Abstract

Although new techniques (i.e., droplet digital-PCR, next-generation sequencing, advanced flow cytometry) are being developed, DNA-based allele-specific real-time quantitative (RQ)-PCR is still the gold standard for sensitive and accurate immunoglobulin/T cell receptor (IG/TR)-based minimal residual disease (MRD) monitoring, allowing the detection of up to 1 leukemic cell in 100,000 normal lymphoid cells. We herewith describe the standard PCR procedure which has been developed and standardized (with minor modification in single labs) through the last 20 years of activity of the EuroMRD Consortium, a volunteer activity of expert laboratories that is continuously providing education, standardization, quality control rounds, and guidelines for interpretation of RQ-PCR data.

Key words

  • Minimal residual disease
  • Immunoglobulin
  • T cell receptor
  • Rearrangement
  • RQ-PCR

This is a preview of subscription content, access via your institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-1-0716-0810-4_6
  • Chapter length: 18 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   119.00
Price excludes VAT (USA)
  • ISBN: 978-1-0716-0810-4
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   159.99
Price excludes VAT (USA)
Hardcover Book
USD   219.99
Price excludes VAT (USA)
Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Cazzaniga G, Biondi A (2005) Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica 90:382–390

    CAS  Google Scholar 

  2. Van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352:1731–1738

    CrossRef  Google Scholar 

  3. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A et al (2010) Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115:3206–3214

    CAS  CrossRef  Google Scholar 

  4. Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grümayer R, Möricke A et al (2011) Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 118:2077–2084

    CAS  CrossRef  Google Scholar 

  5. Brüggemann M, Raff T, Flohr T, Gökbuget N, Nakao M, Droese J et al (2006) Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Blood 107:1116–1123

    CrossRef  Google Scholar 

  6. Nunes V, Cazzaniga G, Biondi A (2017) An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia. Expert Rev Mol Diagn 17:953–963

    CAS  CrossRef  Google Scholar 

  7. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, Wijkhuijs AJ, de Haas V, Roovers E et al (1998) Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 12:2006–2014

    CAS  CrossRef  Google Scholar 

  8. Van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER et al (2007) European Study Group on MRD detection in ALL (ESG-MRD-ALL). Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 21:604–611

    CrossRef  Google Scholar 

  9. van der Velden VH, Panzer-Grümayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A et al (2007) Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 21:706–713

    CrossRef  PubMed  Google Scholar 

  10. Aubin J, Davi F, Nguyen-Salomon F, Leboeuf D, Debert C, Taher M et al (1995) Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies. Leukemia 9:471–479

    CAS  PubMed  Google Scholar 

  11. Szczepanski T, Pongers-Willemse MJ, Langerak AW, Harts WA, Wijkhuijs AJM, van Wering ER et al (1999) Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. Blood 93:4079–4085

    CAS  CrossRef  PubMed  Google Scholar 

  12. Pongers-Willemse MJ, Seriu T, Stolz F, d’Aniello E, Gameiro P, Pisa P et al (1999) Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 13:110–118

    CAS  CrossRef  PubMed  Google Scholar 

  13. van Dongen JJM, Langerak AW, Bruggemann M, Evans PAS, Hummel M, Lavender FL et al (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257–2317

    CrossRef  PubMed  Google Scholar 

  14. Szczepanski T, van der Velden VHJ, Hoogeveen PG, de Bie M, Jacobs DCH, Elisabeth R et al (2004) Vd2-Ja rearrangements are frequent in precursor-B–acute lymphoblastic leukemia but rare in normal lymphoid cells. Blood 103:3798–3804

    CAS  CrossRef  PubMed  Google Scholar 

  15. Boone E, Verhaaf B, Langerak AW (2013) PCR-based analysis of rearranged immunoglobulin or T-cell receptor genes by GeneScan analysis or heteroduplex analysis for clonality assessment in lymphoma diagnostics. Methods Mol Biol 971:65–91

    CAS  CrossRef  PubMed  Google Scholar 

  16. van der Velden VHJ, Wijkhuijs JM, Jacobs DCH, van Wering ER, van Dongen JJM (2002) T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia 16:1372–1380

    CrossRef  PubMed  Google Scholar 

  17. Bruggemann M, van der Velden VHJ, Raff T, Droese J, Ritgen M, Pott C et al (2004) Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia. Leukemia 18:709–719

    CAS  CrossRef  PubMed  Google Scholar 

  18. Verhagen OJHM, Willemse MJ, Breunis WB, Wijkhuijs AJM, Jacobs DCH, Joosten SA et al (2000) Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 14:1426–1435

    CAS  CrossRef  Google Scholar 

  19. van der Velden VHJ, de Bie M, van Wering ER, van Dongen JJM (2006) Immunoglobulin light chain gene in precursor-B-acute lymphoblastic leukemia: characteristics and applicability for the detection of minimal residual disease. Haematologica 91:679–682

    Google Scholar 

  20. Brüggemann M, Kotrová M, Knecht H, Bartram J, Boudjogrha M, Bystry V et al (2019) EuroClonality-NGS Working Group. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia 33:2241–2253

    CrossRef  PubMed  PubMed Central  Google Scholar 

  21. Knecht H, Reigl T, Kotrová M, Appelt F, Stewart P, Bystry V et al (2019) EuroClonality-NGS Working Group. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. Leukemia 33:2254–2265

    CrossRef  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centro Ricerca Tettamanti, Fondazione Tettamanti, Pediatrics, Monza, Italy

    Giovanni Cazzaniga & Simona Songia

  2. Department of Medicine and Surgery, University of Milan Bicocca, Monza, Italy

    Giovanni Cazzaniga & Andrea Biondi

  3. Pediatrics, Ospedale San Gerardo/Fondazione MBBM, Italy

    Andrea Biondi

Authors
  1. Giovanni Cazzaniga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simona Songia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Biondi
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

On Behalf of the EuroMRD Working Group

Corresponding author

Correspondence to Giovanni Cazzaniga .

Editor information

Editors and Affiliations

  1. Immune System Development and Function Unit, Centro de Biologia Molecular "Severo Ochoa", (CSIC/UAM), Madrid, Spain

    César Cobaleda

  2. IBMCC, Laboratory 13, CSIC/Universidad de Salamanca, Salamanca, Spain

    Isidro Sánchez-García

Rights and permissions

Reprints and Permissions

Copyright information

© 2021 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Verify currency and authenticity via CrossMark

Cite this protocol

Cazzaniga, G., Songia, S., Biondi, A., On Behalf of the EuroMRD Working Group. (2021). PCR Technology to Identify Minimal Residual Disease. In: Cobaleda, C., Sánchez-García, I. (eds) Leukemia Stem Cells. Methods in Molecular Biology, vol 2185. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0810-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-0810-4_6

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-0809-8

  • Online ISBN: 978-1-0716-0810-4

  • eBook Packages: Springer Protocols